APS 2010 Chronic Non-Cancer Pain

Fewer Elderly Patients with Moderate-to-Severe Chronic Pain Discontinue Tapentadol Extended-Release vs Oxycodone Controlled-Release Due to Adverse Events

Tapentadol extended-release (ER), an investigational drug, was associated with better gastrointestinal tolerability in elderly patients with moderate-to-severe chronic pain, with fewer discontinuing the study due to treatment-emergent adverse events (TEAEs) than oxycodone controlled-release (CR), investigators concluded in a presentation during the 29th Annual Scientific Meeting of the American Pain Society.

Transmucosal, Oral Opioids Found to be Concordant for Breakthrough Pain in Opioid-Tolerant Patients with Chronic Pain

Determining an effective opioid dose for chronic pain in patients who become opioid tolerant can be challenging. In fact, effective dosing of a rapid-onset transmucosal opioid for breakthrough pain is not related to the around-the-clock dose, studies have shown. However, few data exist on the effective dose of the more traditional, short-acting oral opioids, according a study presented at the 29th Annual Scientific Meeting of the American Pain Society.

EXALGO Provides 24-Hour Management of Moderate-to-Severe Chronic Pain

Patients with moderate-to-severe chronic pain can be successfully converted from prior opioid therapy to EXALGO (hydromorphone HCl) extended-release tablet, an extended-release (ER) oral formulation of hydromorphone HCl, according to a presentation at the American Pain Society 29th Annual Scientific Meeting. Approved by the US Food and Drug Administration on March 1, 2010, EXALGO is the only ER formulation of hydromorphone available in the US.

Comorbid Migraine Does Not Affect Efficacy of Milnacipran in Management of Fibromyalgia

In patients with fibromyalgia, milnacipran efficacy is not affected by the presence of comorbid migraine headache, examination of pooled data from three randomized, double-blind, placebo-controlled clinical trials of the dual serotonin- and norepinephrine-reuptake inhibitor has found.The study was presented at The American Pain Society’s 29th Annual Scientific Meeting.